Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer

Rare

Prisma Health-Upstatemonoclonal_antibodyPhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Rare cohort.

Asset / Sponsor	Phase	Rating
Burosumab Bicetre Hospital	Phase 4	BB
Irinotecan Gradalis, Inc.	Phase 3	B
Crofelemer Napo Pharmaceuticals, Inc.	Phase 2/3	B
Nivestim Hospices Civils de Lyon	Phase 2/3	B
Gemogenovatucel-T Gradalis, Inc.	Phase 3	B

View all 11 →

Same molecule, other indications

Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer is also rated in:

malignant pancreatic neoplasmActive

Indicative · Phase 2

68 / 100

View asset →

biliary tract neoplasmDormant

Indicative · Phase 2

66 / 100

View asset →

pancreatic ductal adenocarcinomaActive

Indicative · Phase 2

66 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →